iBio Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Basis of Presentation (Details)

Basis of Presentation (Details)						1 Months Ended	12 Months Ended
Basis of Presentation (Details)	Aug. 19, 2025 USD ($) $ / shares shares	Apr. 29, 2025 USD ($) $ / shares shares	Jan. 10, 2025 USD ($) $ / shares shares	Nov. 29, 2023 shares	Oct. 07, 2022 shares	Jul. 31, 2025 USD ($) shares	Jun. 30, 2025 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares	Jul. 03, 2024 USD ($) $ / shares
Net cash used in operations \| $							$ 15,304,000	$ 18,554,000
Total current assets \| $							9,721,000	15,672,000
Cash and cash equivalents \| $							8,582,000	$ 14,210,000
Net loss from operations \| $							$ 18,400,000
Common stock, par value \| $ / shares							$ 0.001
Combined price per share of common stock and warrants \| $ / shares							$ 0.76	$ 2.11
Common Stock
Reverse stock split, shares received per share tendered				0.05	0.04
Pre-split shares required for one post-split share of common stock \| shares				20	1
At Market Issuance Sales Agreement \| At-The-Market Offerings \| Subsequent Events
Common stock, shares issued \| shares						305,424
Net proceeds from sale of equity \| $						$ 219,000
At Market Issuance Sales Agreement \| Placement Agents \| At-The-Market Offerings \| Common Stock
Aggregate offering price \| $									$ 7,350,000
Common stock, shares issued \| shares							3,184,899
Net proceeds from sale of equity \| $							$ 2,617,000
Common stock, par value \| $ / shares									$ 0.001
At Market Issuance Sales Agreement \| Placement Agents \| At-The-Market Offerings \| Common Stock \| Subsequent Events
Common stock, shares issued \| shares						305,424
Net proceeds from sale of equity \| $						$ 219,000
2025 Purchase Agreement \| Investors \| Private placement \| Common Stock
Common stock, shares issued \| shares			240,807
Share price on new issues \| $ / shares			$ 2.72
Aggregate gross proceeds \| $			$ 655,000
Warrant Inducement Agreement \| Pre-Funded Warrants
Warrants, shares exercised \| shares		5,626,685
Warrants, exercise price \| $ / shares		$ 0.86
Warrant Inducement Agreement \| Inducement Warrants
Warrants, shares exercised \| shares							0
Warrants, exercise price \| $ / shares		0.86
Proceeds per share (inducement warrants) \| $ / shares		$ 0.125
Proceeds from exercise of warrants \| $		$ 6,200,000
Warrants, shares issued \| shares		11,253,370
Inducement warrants conversion percentage to common shares		200.00%
Warrants, exercisable term		5 years
Underwriting Agreement \| Leerink Partners \| Common Stock \| Subsequent Events
Net proceeds from sale of equity \| $	$ 46,500,000
Aggregate gross proceeds \| $	50,000,000
Transaction costs \| $	$ 3,500,000
Underwriting Agreement \| Leerink Partners \| Common Stock \| Pre-Funded Warrants \| Subsequent Events
Common stock, shares issued \| shares	71,540,000
Warrants, exercise price \| $ / shares	$ 0.001
Underwriting Agreement \| Leerink Partners \| Common Stock \| Series G Warrants \| Subsequent Events
Common stock, shares issued \| shares	35,770,000
Underwriting Agreement \| Leerink Partners \| Common Stock \| Pre-funded Series G Warrants \| Subsequent Events
Common stock, shares issued \| shares	35,770,000
Combined price per share of common stock and warrants \| $ / shares	$ 0.699
Warrants, exercise price \| $ / shares	$ 0.699
Underwriting Agreement \| Leerink Partners \| Common Stock \| Series H Warrants \| Subsequent Events
Common stock, shares issued \| shares	35,770,000
Underwriting Agreement \| Leerink Partners \| Common Stock \| Pre-funded Series H Warrants \| Subsequent Events
Common stock, shares issued \| shares	35,770,000